Evidence map›Paper›PMID 38683491›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2024

Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities.

Manasa Gangadhar Shetty, Padmini Pai, Bipasa Dey, Kapaettu Satyamoorthy, Suranjan Shil, Usha Yogendra Nayak, Ashwini T, Babitha Kampa Sundara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manasa Gangadhar ShettyDepartment of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Padmini PaiDepartment of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Bipasa DeyDepartment of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Kapaettu SatyamoorthyShri Dharmasthala Manjunatheshwara (SDM) University, Manjushree Nagar, Sattur, Dharwad, 580009, Karnataka, India.
Suranjan ShilDepartment of Chemistry, Manipal Centre for Natural Sciences (Centre of Excellence), Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Usha Yogendra NayakDepartment of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Ashwini TDepartment of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Babitha Kampa SundaraDepartment of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. babitha.ks@manipal.edu.ORCID https://orcid.org/0000-0002-9385-9353

Funding

Department of Biotechnology, Ministry of Science and Technology, India BT/PR20046/BIC/101/683/2016
6 · The paper itself

Abstract

backgroundAberrant expression of histone deacetylases (HDACs) and ribonucleotide reductase (RR) enzymes are commonly observed in various cancers. Researchers are focusing on these enzymes in cancer studies with the aim of developing effective chemotherapeutic drugs for cancer treatment. Targeting both HDAC and RR simultaneously with a dual HDAC/RR inhibitor has exhibited enhanced effectiveness compared to monotherapy in cancer treatment, making it a promising strategy.

objectivesThe objective of the study is to synthesize and assess the anti-cancer properties of a 1,10-phenanthroline-based hydroxamate derivative, characterizing it as a novel dual HDAC/RR inhibitor.

methodsThe N

resultsThe structurally confirmed PA exhibited antiproliferative activity in SiHa cells with an IC

conclusionThe present study emphasizes the prospect of designing a potential 1,10-phenanthroline hydroxamic acid derivative as a novel dual HDAC and RR-inhibiting anti-cancer molecule.

Indexed as

Antineoplastic AgentsCell ProliferationHistone Deacetylase InhibitorsHydroxamic AcidsMolecular Docking SimulationPhenanthrolinesApoptosisCell Line, TumorHistone DeacetylasesHumansMolecular Dynamics SimulationRibonucleotide Reductases1,10-phenanthrolineAntineoplastic AgentsHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsPhenanthrolinesRibonucleotide Reductases1,10-PhenanthrolineAnti-cancerDual targetingHDACHydroxamic acidRR

Identifiers

PMID38683491
PMCPMC11087398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.